NeuroOne Medical Technologies ( (NMTC) ) has shared an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
NeuroOne announced a preliminary unaudited revenue increase for the first quarter of fiscal 2025 to a record $6.2 million, significantly up from $1 million in the previous year. The revenue boost includes a $3 million upfront payment from an expanded distribution agreement with Zimmer Biomet for the OneRF™ Ablation System, along with a 227% increase in product revenue to $3.2 million, which reflects the company’s strengthened market position and strategic partnerships.
More about NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation is a medical technology company that specializes in developing and commercializing minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation treatments for neurological disorders such as epilepsy and Parkinson’s disease. The company’s focus is on improving surgical care options, patient outcomes, and reducing procedural costs, with potential applications in other areas like depression, chronic pain, and artificial intelligence.
YTD Price Performance: 31.71%
Average Trading Volume: 172,554
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $33.31M
For an in-depth examination of NMTC stock, go to TipRanks’ Stock Analysis page.
